echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Sichuan pharmaceutical company will win the blockbuster first imitation of $1.4 billion varieties to welcome the first production company

    Sichuan pharmaceutical company will win the blockbuster first imitation of $1.4 billion varieties to welcome the first production company

    • Last Update: 2021-06-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, the first generic drug R&D welcome progress: Hainan Simcere is the first to submit a generic drug listing application for idoxaban tosylate tablets, and Sichuan Pride Times Pharmaceuticals uses generic 3 types of telmisartan and amlodipine tablets for production Enter the stage of administrative approval.
    Both products are drugs for chronic diseases and are only sold by original manufacturers in China.

    Idoxaban tosylate is a selective factor Xa inhibitor developed by Daiichi Sankyo, Japan.


    It was first approved for venous thromboembolism in Japan in 2011, and several new indications have been approved since then.


    At the end of 2018, idoxaban tosylate tablets were officially approved for import by the National Food and Drug Administration, bringing new options for anticoagulant therapy for domestic patients.


    According to data from Mi Nei.


    At present, only Hainan Simcere Pharmaceutical Co.


    , Ltd.


    Telmisartan amlodipine is a compound preparation composed of telmisartan (specific angiotensin II receptor antagonist) and amlodipine besylate (calcium antagonist), used to treat primary hypertension blood pressure.


    At present, only Boehringer Ingelheim's Telmisartan and Amlodipine tablets are on sale in China, and Sichuan Pride Times Pharmaceutical has exclusively submitted the application for the marketing of this product as a generic drug.


    Sichuan Pride Times Pharmaceutical submitted a listing application for telmisartan and amlodipine tablets in October 2018 with imitations of category 3, and entered the administrative approval stage in May 2021, and is expected to win the first imitation.


    ( Minenet database, official website of State Food and Drug Administration, etc.


    Recently, the first generic drug R&D welcome progress: Hainan Simcere is the first to submit a generic drug listing application for idoxaban tosylate tablets, and Sichuan Pride Times Pharmaceuticals uses generic 3 types of telmisartan and amlodipine tablets for production Enter the stage of administrative approval.
    Both products are drugs for chronic diseases and are only sold by original manufacturers in China.

    Idoxaban tosylate is a selective factor Xa inhibitor developed by Daiichi Sankyo, Japan.


    It was first approved for venous thromboembolism in Japan in 2011, and several new indications have been approved since then.


    At the end of 2018, idoxaban tosylate tablets were officially approved for import by the National Food and Drug Administration, bringing new options for anticoagulant therapy for domestic patients.


    According to data from Mi Nei.


    At present, only Hainan Simcere Pharmaceutical Co.


    , Ltd.


    Telmisartan amlodipine is a compound preparation composed of telmisartan (specific angiotensin II receptor antagonist) and amlodipine besylate (calcium antagonist), used to treat primary hypertension blood pressure.
    At present, only Boehringer Ingelheim's Telmisartan and Amlodipine tablets are on sale in China, and Sichuan Pride Times Pharmaceutical has exclusively submitted the application for the marketing of this product as a generic drug.

    Sichuan Pride Times Pharmaceutical submitted a listing application for telmisartan and amlodipine tablets in October 2018 with imitations of category 3, and entered the administrative approval stage in May 2021, and is expected to win the first imitation.
    ( Minenet database, official website of State Food and Drug Administration, etc.
    )

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.